Recursion Pharmaceuticals Inc
RXRXHealthcare|Biotechnology|USA
$3.56
-0.21 (-5.57%)
Tangible Book
$1.08
Clinical Trials (9)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06678659 A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer | Unresectable, Locally Advanced | P1P2 | Recruiting | 170 | RCT, Open-label | REC-1245 |
| NCT05985655 Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors | Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma | P1P2 | Recruiting | 230 | Open-label | GTAEXS617, SoC |
| NCT05552755 Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP) | Familial Adenomatous Polyposis | P1P2 | Recruiting | 67 | Open-label | REC-4881, Placebo |
| NCT07517198 Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors | Solid Tumor, Small Cell Lung Cancer (SCLC) | P1 | Recruiting | 40 | Open-label | EXS74539 |
| NCT06980116 Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies | Relapsed or Refractory B-cell Malignancies, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | P1 | Recruiting | 85 | Open-label | EXS73565 |
| NCT05130866 Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas | Neurofibromatosis Type 2 | P2P3 | Terminated | 25 | RCT, Double-blind | REC-2282, Placebo |
| NCT05085561 The Symptomatic Cerebral Cavernous Malformation Trial of REC-994 | Cerebral Cavernous Malformation | P2 | Completed | 62 | RCT, Double-blind | REC-994, Placebo |
| NCT06005974 A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation | AXIN1 Gene Mutation, APC Gene Mutation | P2 | Terminated | 18 | Open-label | REC-4881 |
| NCT06536465 The Clostridioides Difficile Trial of REC-3964 | Recurrent Clostridioides Difficile Infection | P2 | Terminated | 3 | RCT, Open-label | REC-3964 |